EMPA-REG OUTCOME: The Cardiologist's Point of View
Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patien...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2017-07, Vol.120 (1), p.S53-S58 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S58 |
|---|---|
| container_issue | 1 |
| container_start_page | S53 |
| container_title | The American journal of cardiology |
| container_volume | 120 |
| creator | Pham, Son V., MD Chilton, Robert J., DO |
| description | Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report. |
| doi_str_mv | 10.1016/j.amjcard.2017.05.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1909238350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914917308019</els_id><sourcerecordid>1909238350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c561t-32f60a8fb2a8547cc3a3fe9259753e5abc19d52c09ab882c7a2e40fda5b19703</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EokvhEUCROMAlYcZeJzYHULVaClKrrWDhajnOBByycbGzoL4Nz8KTkWgXkHrhZI30zT-ebxh7jFAgYPmiK-yuczY2BQesCpAFIN5hC1SVzlGjuMsWAMBzjUt9wh6k1E0loizvsxOuSijFUi6YWF9eneXv1-fZ5uN2tblcv8y2XyhbTcE-9OGzT-OzlF0FP4xZaH_9_OTpx0N2r7V9okfH95Rt36y3q7f5xeb83ersIneyxDEXvC3BqrbmVsll5ZywoiXNpa6kIGlrh7qR3IG2tVLcVZbTEtrGyhp1BeKUPT_EXsfwbU9pNDufHPW9HSjsk0ENmgsl5Iw-vYV2YR-H6XMThYiVKhWfKHmgXAwpRWrNdfQ7G28Mgpmlms4cpZpZqgFpJmNT35Nj-r7eUfO364_FCXh9AGiy8d1TNMl5Ghw1PpIbTRP8f0e8upXgej94Z_uvdEPp3zYmcQPmw3zZ-bBYCVCAWvwGNoGb-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1911178682</pqid></control><display><type>article</type><title>EMPA-REG OUTCOME: The Cardiologist's Point of View</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pham, Son V., MD ; Chilton, Robert J., DO</creator><creatorcontrib>Pham, Son V., MD ; Chilton, Robert J., DO</creatorcontrib><description>Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2017.05.011</identifier><identifier>PMID: 28606345</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aorta ; Benzhydryl Compounds - therapeutic use ; Blood pressure ; Cardiovascular ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - prevention & control ; Cardiovascular Physiological Phenomena ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetic Angiopathies - prevention & control ; Glucosides - therapeutic use ; Health risks ; Heart diseases ; Heart failure ; Heart rate ; Hemodynamics - drug effects ; Hospitalization ; Humans ; Hyperglycemia ; Hypertension ; Hypoglycemic Agents - therapeutic use ; Mortality ; Myocardium - metabolism ; Oxygen Consumption ; Patients ; Physiology ; Risk Factors ; Rodents ; Sodium-Glucose Transporter 2 - antagonists & inhibitors ; Stroke ; Ventricle ; Ventricular Function, Left</subject><ispartof>The American journal of cardiology, 2017-07, Vol.120 (1), p.S53-S58</ispartof><rights>The Author(s)</rights><rights>2017 The Author(s)</rights><rights>Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Jul 1, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c561t-32f60a8fb2a8547cc3a3fe9259753e5abc19d52c09ab882c7a2e40fda5b19703</citedby><cites>FETCH-LOGICAL-c561t-32f60a8fb2a8547cc3a3fe9259753e5abc19d52c09ab882c7a2e40fda5b19703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002914917308019$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28606345$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pham, Son V., MD</creatorcontrib><creatorcontrib>Chilton, Robert J., DO</creatorcontrib><title>EMPA-REG OUTCOME: The Cardiologist's Point of View</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.</description><subject>Aorta</subject><subject>Benzhydryl Compounds - therapeutic use</subject><subject>Blood pressure</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cardiovascular Physiological Phenomena</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetic Angiopathies - prevention & control</subject><subject>Glucosides - therapeutic use</subject><subject>Health risks</subject><subject>Heart diseases</subject><subject>Heart failure</subject><subject>Heart rate</subject><subject>Hemodynamics - drug effects</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hypertension</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Mortality</subject><subject>Myocardium - metabolism</subject><subject>Oxygen Consumption</subject><subject>Patients</subject><subject>Physiology</subject><subject>Risk Factors</subject><subject>Rodents</subject><subject>Sodium-Glucose Transporter 2 - antagonists & inhibitors</subject><subject>Stroke</subject><subject>Ventricle</subject><subject>Ventricular Function, Left</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcFu1DAQhi0EokvhEUCROMAlYcZeJzYHULVaClKrrWDhajnOBByycbGzoL4Nz8KTkWgXkHrhZI30zT-ebxh7jFAgYPmiK-yuczY2BQesCpAFIN5hC1SVzlGjuMsWAMBzjUt9wh6k1E0loizvsxOuSijFUi6YWF9eneXv1-fZ5uN2tblcv8y2XyhbTcE-9OGzT-OzlF0FP4xZaH_9_OTpx0N2r7V9okfH95Rt36y3q7f5xeb83ersIneyxDEXvC3BqrbmVsll5ZywoiXNpa6kIGlrh7qR3IG2tVLcVZbTEtrGyhp1BeKUPT_EXsfwbU9pNDufHPW9HSjsk0ENmgsl5Iw-vYV2YR-H6XMThYiVKhWfKHmgXAwpRWrNdfQ7G28Mgpmlms4cpZpZqgFpJmNT35Nj-r7eUfO364_FCXh9AGiy8d1TNMl5Ghw1PpIbTRP8f0e8upXgej94Z_uvdEPp3zYmcQPmw3zZ-bBYCVCAWvwGNoGb-w</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Pham, Son V., MD</creator><creator>Chilton, Robert J., DO</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20170701</creationdate><title>EMPA-REG OUTCOME: The Cardiologist's Point of View</title><author>Pham, Son V., MD ; Chilton, Robert J., DO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c561t-32f60a8fb2a8547cc3a3fe9259753e5abc19d52c09ab882c7a2e40fda5b19703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aorta</topic><topic>Benzhydryl Compounds - therapeutic use</topic><topic>Blood pressure</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cardiovascular Physiological Phenomena</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetic Angiopathies - prevention & control</topic><topic>Glucosides - therapeutic use</topic><topic>Health risks</topic><topic>Heart diseases</topic><topic>Heart failure</topic><topic>Heart rate</topic><topic>Hemodynamics - drug effects</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hypertension</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Mortality</topic><topic>Myocardium - metabolism</topic><topic>Oxygen Consumption</topic><topic>Patients</topic><topic>Physiology</topic><topic>Risk Factors</topic><topic>Rodents</topic><topic>Sodium-Glucose Transporter 2 - antagonists & inhibitors</topic><topic>Stroke</topic><topic>Ventricle</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pham, Son V., MD</creatorcontrib><creatorcontrib>Chilton, Robert J., DO</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pham, Son V., MD</au><au>Chilton, Robert J., DO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EMPA-REG OUTCOME: The Cardiologist's Point of View</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>120</volume><issue>1</issue><spage>S53</spage><epage>S58</epage><pages>S53-S58</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><abstract>Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28606345</pmid><doi>10.1016/j.amjcard.2017.05.011</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2017-07, Vol.120 (1), p.S53-S58 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1909238350 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aorta Benzhydryl Compounds - therapeutic use Blood pressure Cardiovascular Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - prevention & control Cardiovascular Physiological Phenomena Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Diabetic Angiopathies - prevention & control Glucosides - therapeutic use Health risks Heart diseases Heart failure Heart rate Hemodynamics - drug effects Hospitalization Humans Hyperglycemia Hypertension Hypoglycemic Agents - therapeutic use Mortality Myocardium - metabolism Oxygen Consumption Patients Physiology Risk Factors Rodents Sodium-Glucose Transporter 2 - antagonists & inhibitors Stroke Ventricle Ventricular Function, Left |
| title | EMPA-REG OUTCOME: The Cardiologist's Point of View |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T06%3A54%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EMPA-REG%20OUTCOME:%20The%20Cardiologist's%20Point%20of%C2%A0View&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Pham,%20Son%20V.,%20MD&rft.date=2017-07-01&rft.volume=120&rft.issue=1&rft.spage=S53&rft.epage=S58&rft.pages=S53-S58&rft.issn=0002-9149&rft.eissn=1879-1913&rft_id=info:doi/10.1016/j.amjcard.2017.05.011&rft_dat=%3Cproquest_cross%3E1909238350%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1911178682&rft_id=info:pmid/28606345&rft_els_id=S0002914917308019&rfr_iscdi=true |